Tiziana Life Sciences Ltd (NASDAQ:TLSA – Get Free Report) saw a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 567,600 shares, a drop of 39.2% from the February 13th total of 934,300 shares. Currently, 0.8% of the shares of the stock are sold short. Based on an average trading volume of 955,300 shares, the days-to-cover ratio is currently 0.6 days.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the business. Sanctuary Advisors LLC bought a new stake in Tiziana Life Sciences during the 3rd quarter worth about $864,000. Zhang Financial LLC raised its holdings in Tiziana Life Sciences by 34.3% during the 4th quarter. Zhang Financial LLC now owns 93,187 shares of the company’s stock worth $65,000 after purchasing an additional 23,800 shares during the last quarter. Geode Capital Management LLC raised its holdings in Tiziana Life Sciences by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 245,722 shares of the company’s stock worth $171,000 after purchasing an additional 27,041 shares during the last quarter. Finally, Bison Wealth LLC bought a new stake in Tiziana Life Sciences during the 4th quarter worth about $30,000.
Tiziana Life Sciences Stock Up 6.1 %
Tiziana Life Sciences stock opened at $1.57 on Monday. The stock has a 50-day simple moving average of $0.92 and a 200 day simple moving average of $0.92. Tiziana Life Sciences has a 12-month low of $0.41 and a 12-month high of $1.91.
Tiziana Life Sciences Company Profile
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
Further Reading
- Five stocks we like better than Tiziana Life Sciences
- The How and Why of Investing in Gold Stocks
- 3 Dividend Stocks Offering Higher Yields and Bullish Forecasts
- There Are Different Types of Stock To Invest In
- EU-U.S. Military Shift: A Catalyst for These 3 Stocks
- 3 Monster Growth Stocks to Buy Now
- How to Build the Ultimate Everything ETF Portfolio
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
